More and more cancer patients are surviving the disease but suffer with debilitating pain as a result of chemotherapy treatment, particularly in the feet and hands. The nerve damage can affect the patient’s ability to walk and use their hands. But an NBC News affiliate broadcast this new report on October 11 about a new clinical study by the University of Wisconsin which determined Calmare’s MC-5A scrambler therapy is the first known therapy to show measurable results in helping to alleviate CIPN pain. “This technology has consistently shown very impressive results in our blind study, ” reports Toby Campbell, MD, chief of Palliative Medicine, University of Wisconsin.
As a result, a larger more extensive study has been approved. For anyone interested in participating in the study at the University of Wisconsin-Madison, call 800-622-8922.
Dr. Michael J. Cooney
Rutherford Allied Medical Group